Press Releases Amgen Inc.

Equities

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 15/05/2026 BST			5-day change	1st Jan Change
326.31 ^USD	-2.22%		-1.62%	-0.31%

05-15	Incorrectly tagged Kissei alert withdrawn	RE
05-15	Amgen's rare disease drug linked to deaths, liver injuries in Japan, Kissei reports	RE

Press Releases

05-16	Amgen : Statement on TAVNEOS® (avacopan)	PU
05-15	Amgen : 2026 Annual Meeting of Stockholders Presentation Non GAAP Reconciliations	PU
05-12	Amgen : The Story of Maridebart Cafraglutide (MariTide)	PU
05-07	AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE	PR
05-06	Inside Amgen’s Next-Generation Labs: Powering Faster, Smarter Small Molecule Drug Discovery	PU
05-04	AMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR	PR
05-01	Amgen : C O R R E C T I O N Amgen/	PU
04-30	Amgen : Highlights from Amgen's 2026 First Quarter Earnings Report	PU
04-30	Amgen : Q1 2026 Earnings Slides FINAL 04.30.26	PU
04-30	Amgen: Q1 Earnings Snapshot	AQ
04-30	/C O R R E C T I O N -- Amgen/	PR
04-29	Biocon Launches Denosumab Biosimilars	AQ
04-27	AMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL RESULTS	AQ
04-24	AMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL RESULTS	PR
04-22	AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER	PR
04-13	Amgen And Shanghai Henlius/Organon Settle Denosumab BPCIA Litigation	AQ
04-06	AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE	PR
03-28	REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS	PR
03-05	AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE	PR
03-04	AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND	PR
02-27	FDA Approves Accord's FILKRI (Filgrastim-laha), A Biosimilar To NEUPOGEN	AQ
02-24	AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE	PR
02-16	Hikma Launches Denosumab Biosimilars ENOBY And XTRENBO	AQ
02-13	AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT	PR
02-12	Amgen : European Commission Approves Amgen's UPLIZNA® For Generalized Myasthenia Gravis	PU